IKT (Inhibikase Pharma) נכסי החברה

This price evolution chart demonstrates the dynamics of Inhibikase Therapeutics (IKT), whose total assets amount to 126.23. The company operates modern laboratories for developing Parkinson's disease medications equipped with updated hardware. Current revenue is based on partnership agreements and grants, with profits expected from future therapy sales. Meanwhile, molecule synthesis is fully outsourced to external contractors, creating a significant dependency on third-party manufacturers.

The total assets chart for Inhibikase Therapeutics (IKT) reflects the material base of the company, which invests in AI platforms for the automated modeling of Parkinson's disease drugs. This indicator measures the total volume of resources and property controlled by the business, including equity and external liabilities. The value is calculated inversely via return on assets (ROA), allowing for the tracking of the enterprise's physical scale. The metric's dynamics help determine the balance between technological capacity and the risks of a deep capital drawdown.